IN VIVO

metrics 2024

Exploring the frontiers of pharmacology and genetics.

Introduction

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

Metrics 2024

SCIMAGO Journal Rank0.56
Journal Impact Factor1.80
Journal Impact Factor (5 years)1.90
H-Index72
Journal IF Without Self1.80
Eigen Factor0.01
Normal Eigen Factor1.38
Influence0.41
Immediacy Index0.40
Cited Half Life4.40
Citing Half Life7.40
JCI0.48
Total Documents4709
WOS Total Citations5847
SCIMAGO Total Citations20282
SCIMAGO SELF Citations1409
Scopus Journal Rank0.56
Cites / Document (2 Years)1.88
Cites / Document (3 Years)2.08
Cites / Document (4 Years)2.11

Metrics History

Rank 2024

Scopus

General Biochemistry, Genetics and Molecular Biology in Biochemistry, Genetics and Molecular Biology
Rank #91/221
Percentile 58.82
Quartile Q2
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #169/313
Percentile 46.01
Quartile Q3
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #147/230
Percentile 36.09
Quartile Q3

IF (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 130/189
Percentile 31.50
Quartile Q3

JCI (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 127/189
Percentile 32.80
Quartile Q3

Quartile History

Similar Journals

Biomedicines

Connecting researchers to drive impactful biomedical discoveries.
Publisher: MDPIISSN: Frequency: 12 issues/year

Biomedicines, published by MDPI, is a prestigious open-access journal dedicated to the rapidly evolving fields of biochemistry, genetics, and molecular biology, as well as broader aspects of medicine. Since its inception in 2013, Biomedicines has established itself as a leading platform for researchers, practitioners, and students to disseminate high-quality research and innovative findings, reflected in its impressive Q1 ranking in both the Biochemistry, Genetics and Molecular Biology and Medicine categories. With its commitment to accessibility and impactful scholarship, the journal has quickly garnered an international readership, positioning itself as a vital resource in advancing scientific knowledge and fostering collaboration in the biomedical community. Operating from its headquarters in Basel, Switzerland, Biomedicines continues to thrive with features such as rigorous peer review and a fast publication process, making it an essential journal for those looking to contribute to and stay updated in their respective fields.

LIFE SCIENCES

Advancing knowledge in the life sciences since 1962.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0024-3205Frequency: 24 issues/year

LIFE SCIENCES, published by PERGAMON-ELSEVIER SCIENCE LTD, is an esteemed international journal that has been advancing the field since its inception in 1962. With an ISSN of 0024-3205 and an E-ISSN of 1879-0631, it serves as a critical forum for researchers, professionals, and students within the realms of biochemistry, genetics, molecular biology, medicine, and pharmacology. Currently ranked in the Q1 category across multiple disciplines, including a remarkable 2nd rank in General Pharmacology, Toxicology, and Pharmaceutics, the journal maintains a prestigious position in academic circles, evidenced by its high impact factor and significant percentile ranks. While LIFE SCIENCES is not an open-access journal, it remains dedicated to publishing high-quality, peer-reviewed research that pushes the boundaries of knowledge and fosters innovation. With converged research interests leading into 2024, LIFE SCIENCES continues to be a pivotal resource for the dissemination of influential findings, making it an indispensable tool for those engaged in the life sciences.

JOURNAL OF BIOMEDICAL SCIENCE

Transforming discoveries into impactful biomedical advancements.
Publisher: BMCISSN: 1021-7770Frequency: 1 issue/year

JOURNAL OF BIOMEDICAL SCIENCE, published by BMC, is a premier Open Access journal dedicated to the rapid dissemination of research in the fields of biomedical science, encompassing crucial areas such as biochemistry, cell biology, clinical biochemistry, and more. Since its inception in 1993, the journal has established itself as a leading publication, currently boasting a remarkable impact factor and quality as evidenced by its Q1 quartile rankings across multiple categories in 2023. With an impressive track record, including a Scopus ranking in the top percentiles across several disciplines, it serves as a vital resource for researchers, professionals, and students who are keen on advancing their knowledge in biomedicine. The journal operates under a fully Open Access model, ensuring that all published articles are freely available to the global research community, thus contributing to the broader dissemination and accessibility of scientific knowledge. Based in the United Kingdom, JOURNAL OF BIOMEDICAL SCIENCE is committed to fostering innovation and collaboration in research, appealing to those aiming to make impactful contributions to the biomedical sphere.

FASEB BioAdvances

Advancing Knowledge in Biochemistry and Beyond
Publisher: WILEYISSN: Frequency: 12 issues/year

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Driving Progress Through Peer-Reviewed Research
Publisher: WILEYISSN: 0959-9673Frequency: 6 issues/year

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, published by Wiley, is a leading peer-reviewed journal dedicated to the field of experimental pathology. With an ISSN of 0959-9673 and E-ISSN 1365-2613, the journal has been a vital resource for researchers and professionals since its inception in 1990, covering a broad spectrum of topics within pathology, cell biology, and molecular biology. The journal's relevancy is underscored by its Q2 ranking in Pathology and Forensic Medicine and Q3 rankings in both Cell Biology and Molecular Biology, as of 2023, reflecting its significant contribution to the scientific community. Although it does not currently offer open access options, readers can benefit from its insightful research articles and reviews that guide advancements in diagnostic pathology and therapeutic strategies. As the journal continues to evolve, it remains committed to facilitating the exchange of innovative ideas and findings that drive progress in experimental pathology and related fields, making it an indispensable platform for scientists, clinicians, and students alike.

EXPERIMENTAL AND MOLECULAR MEDICINE

Elevating biomedical knowledge through peer-reviewed excellence.
Publisher: SPRINGERNATUREISSN: 1226-3613Frequency: 12 issues/year

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

BIOMEDICAL RESEARCH-TOKYO

Advancing Biomedical Knowledge Since 1980
Publisher: BIOMEDICAL RESEARCH PRESS LTDISSN: 0388-6107Frequency: 6 issues/year

BIOMEDICAL RESEARCH-TOKYO is an esteemed interdisciplinary journal published by BIOMEDICAL RESEARCH PRESS LTD, dedicated to disseminating pioneering research and advancements in the fields of biochemistry, genetics, and medicine. Since its inception in 1980, the journal has established itself as a reputable source of knowledge, contributing significantly to the global scientific community with its strong emphasis on innovative findings and methodologies. With a consistent presence in the Q3 quartile for both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023, it continues to attract a diverse range of research articles. While the journal does not operate as an open access platform, it remains an essential resource for researchers, professionals, and students seeking to further their understanding of biomedical sciences. Located in Sapporo, Japan, this journal fosters collaboration and knowledge sharing among the international biomedical research community, engaging readers through its compelling studies that span from 1980 to 2024.

ANTICANCER RESEARCH

Illuminating Paths in Cancer Treatment and Prevention
Publisher: INT INST ANTICANCER RESEARCHISSN: 0250-7005Frequency: 12 issues/year

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

Molecular Biomedicine

Pioneering Discoveries in Molecular Biology and Medicine
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Molecular Biomedicine is a prestigious peer-reviewed journal published by SpringerNature, dedicated to advancing the fields of molecular biology and molecular medicine. With a commendable Q1 ranking in both categories for 2023, this journal stands out for its rigorous exploration of the biochemical processes underlying health and disease. Operating out of Germany, Molecular Biomedicine aims to provide comprehensive insights into cutting-edge research, facilitating interdisciplinary collaboration among researchers, healthcare professionals, and students alike. The journal's impact is reflected in its Scopus rankings, placing it in the upper echelons of the fields of biochemistry, genetics, and molecular biology. As an open access platform, it commits to disseminating knowledge widely, ensuring that pivotal discoveries are accessible to all. Researchers looking to publish in a dynamic environment that prioritizes innovation and application in the biomedical sciences will find Molecular Biomedicine an ideal outlet for their work.

Sovremennye Tehnologii v Medicine

Advancing Healthcare with Cutting-Edge Technologies
Publisher: NIZHNIY NOVGOROD STATE MEDICAL ACADISSN: 2076-4243Frequency: 6 issues/year

Sovremennye Tehnologii v Medicine is a prominent academic journal dedicated to the exploration and dissemination of contemporary technologies in the field of medicine. Published by the esteemed Nizhniy Novgorod State Medical Academy, this journal serves as a vital platform for researchers, healthcare professionals, and students seeking to stay at the forefront of advancements in biochemistry, genetics, and molecular biology. With an impact factor that positions it within the Q3 quartile for both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023, it highlights a commitment to quality research. The journal, identified by the ISSN 2076-4243, provides a rich repository of knowledge for those interested in the innovative applications of medical science, contributing significantly to the academic discourse and the practical world of healthcare. With an open access option, it ensures that its valuable content is readily accessible to a global audience, fostering collaborative advancements in modern medical practices.